FRMEP
FIRST MERCHANTS CORP
$25.15
-0.40%
$1.6B
No data for this timeframe.
Vol
Market Cap$1.6B
Cap SizeSmall Cap
SEC Reports3
Recent Activity
May 19, 2026
SEC
First Merchants Corporation announced the retirement of director Gary Lehman and the appointment of Paul Fultz to fill t
8-K — Impact 2/10
May 19, 2026
SEC
First Merchants Corporation declared a $0.37 per share common stock cash dividend, payable on June 19, 2026 to holders o
8-K — Impact 2/10
Apr 22, 2026
SEC
First Merchants Corporation reported first quarter 2026 earnings with GAAP diluted EPS of $0.45, missing prior year's $0
8-K — Impact 6/10
Analyst Ratings
2Strong Buy
7Buy
3Hold
0Sell
0Strong Sell
Latest Reports
NEUTRAL
8-K
2/10
First Merchants Corporation announced the retirement of director Gary Lehman and the appointment of Paul Fultz to fill t
May 19, 2026
NEUTRAL
8-K
2/10
First Merchants Corporation declared a $0.37 per share common stock cash dividend, payable on June 19, 2026 to holders o
May 19, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 2 neutral. Avg impact: 3.3/10.
NEUTRAL
8-K
2/10
First Merchants Corporation announced the retirement of director Gary Lehman and the appointment of
May 19, 2026
NEUTRAL
8-K
2/10
First Merchants Corporation declared a $0.37 per share common stock cash dividend, payable on June 1
May 19, 2026
MIXED
8-K
6/10
First Merchants Corporation reported first quarter 2026 earnings with GAAP diluted EPS of $0.45, mis
Apr 22, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 75% buy across 12 analysts — 2 strong buy, 7 buy, 3 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.2B | 18.8% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.2B | 19.4% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.8B | 17.7% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.9B | 5.4% | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 7 | 3 | 0 | 0 | 75% | |
| May 1, 2026 | 2 | 7 | 3 | 0 | 0 | 75% | |
| Apr 1, 2026 | 2 | 7 | 3 | 0 | 0 | 75% | |
| Mar 1, 2026 | 2 | 7 | 3 | 0 | 0 | 75% | |
| Feb 1, 2026 | 2 | 6 | 3 | 0 | 0 | 73% | |
| Jan 1, 2026 | 3 | 6 | 3 | 0 | 0 | 75% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.